Viva Biotech Holdings (FRA:VB0) Other Stockholders Equity: €45.2 Mil (As of Dec. 2025)


FRA:VB0 Viva Biotech Holdings FRA:VB0
42 GF Score
Price €0.13
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Other Stockholders Equity?

Viva Biotech Holdings FRA:VB0 +4.88% 42 Other Stockholders Equity is €45.2 Mil as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 42/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Viva Biotech Holdings's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €45.2 Mil.

Viva Biotech Holdings's quarterly Other Stockholders Equity declined from Dec. 2024 (€48.8 Mil) to Jun. 2025 (€41.7 Mil) but then increased from Jun. 2025 (€41.7 Mil) to Dec. 2025 (€45.2 Mil).

Viva Biotech Holdings's annual Other Stockholders Equity increased from Dec. 2023 (€47.1 Mil) to Dec. 2024 (€48.8 Mil) but then declined from Dec. 2024 (€48.8 Mil) to Dec. 2025 (€45.2 Mil).

Viva Biotech Holdings Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Other Stockholders Equity Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.06 50.89 47.08 48.77 45.25

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.08 0.00 48.77 41.66 45.25
FRA:VB0
42GF Score
Viva Biotech Holdings FRA:VB0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viva Biotech Holdings Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €45.2 Mil mean?
Viva Biotech Holdings (FRA:VB0) has a Other Stockholders Equity of €45.2 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Other Stockholders Equity too high?
Viva Biotech Holdings' current Other Stockholders Equity is €45.2 Mil. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Other Stockholders Equity compare to VRTX and REGN?
Viva Biotech Holdings' Other Stockholders Equity of €45.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Other Stockholders Equity is €45.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 61.3% above its estimated fair value. The current Other Stockholders Equity is €45.2 Mil. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Other Stockholders Equity is €45.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.13 is trading 61.3% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Other Stockholders Equity: €45.2 Mil
  • GF Value™: €0.08 vs. price of €0.13 (61.3% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score

Get the complete analysis for FRA:VB0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.08
GF Value